Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia News

News
The Ongoing Impact of COVID-19 on Caregivers of Patients With Chronic Lymphocytic Leukemia
03/15/2023
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the...
03/15/2023
Journal of Clinical Pathways
News
Elevated Risk of Atrial Fibrillation or Stroke in Patients With CLL Receiving Ibrutinib Treatment Has Minimal Impact on TTNT and TTD
02/23/2023
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the...
02/23/2023
Journal of Clinical Pathways
News
Use of Ibrutinib as Initial Therapy for Chronic Lymphocytic Leukemia in Real-World Setting Aligns With Clinical Trials
02/14/2023
According to findings from a systematic literature review, real-world data indicates that the use of the oral BTKi, ibrutinib, as initial therapy for the treatment of CLL, including patients who are classified as having high-risk genomic...
According to findings from a systematic literature review, real-world data indicates that the use of the oral BTKi, ibrutinib, as initial therapy for the treatment of CLL, including patients who are classified as having high-risk genomic...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
Spatial Organization and Early Signaling of the B-Cell Receptor in CLL
10/06/2022
Immunoglobulin G (IgG) class-switched mutated chronic lymphocytic leukemia (M-CLL) likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity, according to a recent study.
Immunoglobulin G (IgG) class-switched mutated chronic lymphocytic leukemia (M-CLL) likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity, according to a recent study.
Immunoglobulin G (IgG)...
10/06/2022
Journal of Clinical Pathways
News
Disease Progression and Clinical Outcomes Among Patients With CLL Receiving Ibrutinib
09/20/2022
Among patients with CLL with disease progression who were treated with ibrutinib, overall survival was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy or venetoclax-based treatment compared to other...
Among patients with CLL with disease progression who were treated with ibrutinib, overall survival was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy or venetoclax-based treatment compared to other...
Among patients with CLL with...
09/20/2022
Journal of Clinical Pathways
News
Exploring Prognostic Value of Genetic Testing at Diagnosis in Chronic Lymphocytic Leukemia
08/24/2022
Findings from a recent study confirmed the prognostic value of immunoglobulin heavy chain mutational status at diagnosis for overall survival and time to first treatment in patients with chronic lymphocytic leukemia.
Findings from a recent study confirmed the prognostic value of immunoglobulin heavy chain mutational status at diagnosis for overall survival and time to first treatment in patients with chronic lymphocytic leukemia.
Findings from a recent study...
08/24/2022
Journal of Clinical Pathways
News
Patient-Reported Outcomes in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia
08/18/2022
A real-world analysis of patient-reported outcomes in CLL/SLL revealed that quality-of-life scores remained stable over the first 12 months of treatment.
A real-world analysis of patient-reported outcomes in CLL/SLL revealed that quality-of-life scores remained stable over the first 12 months of treatment.
A real-world analysis of...
08/18/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use